Save up -80% on Rotigotine
|Note: this is a drug discount program, not an insurance plan.|
|RX BIN: 015558||RX PCN: HT||Group ID: DDN6600||Card Holder ID: DDN6600|
|Pharmacists and Patients support.|
2019 Price of Neupro
|$664||30 patches/2 mg|
|price without discount in nearest pharmacy. Price may vary.|
We offer free Rotigotine coupons and discounts that may help you save up to 80% off the retail price in your local pharmacy. Just print your coupon! It’s ready to use and never expire. Present your discount card in most local pharmacies to get a discount on Rotigotine every time. What are you waiting for? Claim your prescription drug card now!
Get your Prescription
It’s safe and free
Buy drugs in pharmacy
Save money each time
Rotigotine volume of distribution
The weight normalized apparent volume of distribution, (Vd/F), in humans is approximately 84 L/kg after repeated dose administration.
Discount Cards 16,000+
Clients Benefit 29%
Total savings $4,735,080
What is Rotigotine
Rotigotine (Neupro) is a non-ergoline dopamine agonist indicated for the treatment of Parkinson‘s disease (PD) and restless legs syndrome (RLS) in Europe and the United States. It is formulated as a once-daily transdermal patch which provides a slow and constant supply of the drug over the course of 24 hours. Like other dopamine agonists, rotigotine has been shown to possess antidepressant effects and may be useful in the treatment of depression as well. Rotigotine was developed by Aderis Pharmaceuticals. In 1998, Aderis licensed worldwide development and commercialization rights for rotigotine to the German pharmaceutical company Schwarz Pharma (today a subsidiary of the Belgian company UCB S.A.). The drug has been approved by the EMEA for use in Europe in 2006 and is today being sold in several European countries. In 2007, the Neupro patch was approved by the Food and Drug Administration (FDA) as the first transdermal treatment of Parkinson’s disease in the United States. However, as of 2008, Schwarz Pharma has recalled all Neupro patches in the United States and some in Europe because of problems with the delivery mechanism. Rotigotine has been authorized as a treatment for RLS since August 2008.
Rotigotine mechanism of action
Rotigotine, a member of the dopamine agonist class of drugs, is delivered continuously through the skin (transdermal) using a silicone-based patch that is replaced every 24 hours. A dopamine agonist works by activating dopamine receptors in the body, mimicking the effect of the neurotransmitter dopamine. The precise mechanism of action of rotigotine as a treatment for Restless Legs Syndrome is unknown but is thought to be related to its ability to stimulate dopamine
Dosage forms of Rotigotine
Humans and other mammals
Indication of Rotigotine
For use/treatment in neurologic disorders and parkinson’s disease as well as moderate-to-severe primary Restless Legs Syndrome.
Toxicity of Rotigotine
The most likely symptoms of overdose would be those related to the pharmacodynamic profile of a dopamine agonist, including nausea, vomiting, hypotension, involuntary movements, hallucinations, confusion, convulsions, and other signs of excessive dopaminergic stimulation.
RX24 Drugs Disclaimer: before buying a Rotigotine on prescription, consult your healthcare provider. Content on this page is provided for informational purposes only. Any use of this information is at your own risk.